IDEXX Laboratories Inc. (IDXX) demonstrated resilience with strong Q4 2025 earnings, exceeding revenue and EPS expectations. Despite a lowered price target from BTIG due to concerns about 2026 guidance, the company maintains high profitability and growth in its companion animal business. Headwinds include fewer pet visits impacting operating margins, which IDEXX plans to offset with new InVueDx system placements and price growth.
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
IDEXX Laboratories Inc. (IDXX) Shows Resilience as Analysts Reassess Targets
IDEXX Laboratories Inc. (IDXX) demonstrated resilience with strong Q4 2025 earnings, exceeding revenue and EPS expectations. Despite a lowered price target from BTIG due to concerns about 2026 guidance, the company maintains high profitability and growth in its companion animal business. Headwinds include fewer pet visits impacting operating margins, which IDEXX plans to offset with new InVueDx system placements and price growth.